Stryker Reports Q1 Results, Raises Full-Year Guidance

Stryker has reported its operating results for the first quarter of 2025.

The company’s $5.9 billion of net sales in Q1 grew 11.9% in the quarter. Organic net sales rose 10.1%, which includes 9.4% from increased unit volume and 0.7% from higher prices.

Stryker’s MedSurg and Neurotechnology revenues of $3.5 billion reflect a 13.4% growth in the quarter. Organic net sales swelled 10.7%— 9.5% from increased unit volume and 1.2% from higher prices.

Orthopaedics sales reached $2.4 billion, increasing 9.7 % in the quarter. Organic net sales increased 9.3% in the quarter including 9.3% from increased unit volume.

Reported net earnings, however, dropped 17% to $654 million in Q1. Net earnings per diluted share of $1.69 slid 17.6% in the quarter. Reported gross profit margin and reported operating income margin were 63.8% and 14.3% in the quarter.

As a result, Stryker raised its full-year 2025 organic net sales growth guidance range to 8.5-9.5%. Adjusted net earnings per diluted share is expected to be in the range of $13.20-13.45.

“Our 2024 momentum continued into the first quarter as we delivered double-digit organic sales growth and continued to expand adjusted operating margins,” said Kevin A. Lobo, Stryker’s chair and CEO. “We remain confident in our sales and earnings power for 2025, fueled by the strength of procedural volumes, demand for our capital products and our commercial execution.”

Notable Q1 and recent developments

• Sold U.S. spine business to Viscogliosi Brothers to create VB Spine
• Acquired Inari Medical for $4.9 billion
• Introduced Mako Total Hip and Mako 4 at the AAOS annual meeting
• Rolled out Sync Badge for hands-free hospital communication